Brief: Celltrion Inc Says High Infliximab Trough Levels Are Associated With Low Risk Of Relapse When Switching To Subcutaneous Infliximab In Patients With Inflammatory Bowel Disease, Suggests New Data Presented At ECCO 2022 Virtual Congress
18/02/2022 11:40
Feb 18 (Reuters) - Celltrion Inc 068270.KS :
* HIGH INFLIXIMAB TROUGH LEVELS ARE ASSOCIATED WITH LOW RISK
OF
RELAPSE WHEN SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS
WITH INFLAMMATORY BOWEL DISEASE, SUGGESTS NEW DATA PRESENTED AT
ECCO 2022 VIRTUAL CONGRESS
Source text for Eikon: ID:nBw5DQwB8a
Further company coverage: 068270.KS
((reuters.briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won